Notifications

Home

Stocks
- Stock Screener
- Market Movers
- Insider Trades
- Upcoming Earnings
- Upcoming Dividends
Options
- Unusual Options Activity
- Implied Volatility Rank
- Volatility %Change
News
Upcoming IPOs

Newamsterdam Pharma Company N.V. (NAMS)

$28.53 +1.28 (4.70%)

Overview
Financial
Short Interest
Institutional Holdings
Dividends
Charts

Market Cap	3.22B
Revenue (ttm)	22.50M
Net Income (ttm)	-203.82M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-905.87%
Debt to Equity Ratio	0.00

Volume	1,032,200
Avg Vol	1,095,838
Day's Range	N/A - N/A
Shares Out	119.54M
Stochastic %K	42%
Beta	0.10
Analysts	Strong Sell
Price Target	$51.57

Company Profile

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease. It is developing Obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease...

Industry: Biotechnology

Sector: Healthcare

Phone: 31 35 206 2971

Website: www.newamsterdampharma.com

Address:

Gooimeer 2-35, Naarden, Netherlands

JFDI Aug. 19 at 7:48 PM

$NAMS base on base

0 · Reply

Good2go Aug. 18 at 3:43 PM

$EIX $EBAY $ENB even $NAMS All in the green today oddly enough.

0 · Reply

profitsforall Aug. 17 at 8:45 PM

$NAMS NOW now..below $32.X

0 · Reply

profitsforall Aug. 17 at 8:44 PM

$NAMS

0 · Reply

appayip Aug. 17 at 9:45 AM

$NAMS what is the price you would add or open position?

1 · Reply

CH_Expat Aug. 17 at 8:49 AM

$NAMS @masonat Thoughts about the 500k put position from Perceptive Advisors?

2 · Reply

Finlay2 Aug. 14 at 5:03 PM

$NAMS hey guys - anyone worried about the decrease in small hdl particles with obi?

1 · Reply

cubie Aug. 13 at 4:41 PM

$WYFI $NBIS oh wait its get betters😆 $QS baggie eh. so u got qs WRONG WYFI WRONG $CBRS WRONG. $NAMS WRONG bruh, when cubie teaches u fkng learn. with ur track record , no wonder u cant learn😂🤣. Cant teach stupid indeed😆

1 · Reply

newfguy Aug. 7 at 12:25 AM

$NAMS watched all 3 hours of investor day presentation. EU launch end of 26/early 27. US NDA w FDA first half 27. patience will be rewarded

0 · Reply

newfguy Aug. 6 at 9:24 PM

$NAMS 1.65M shares traded today

0 · Reply

NewAmsterdam Pharma price target lowered to $50 from $51 at RBC Capital

Aug 5, 2026, 9:00 AM EDT - 14 days ago

NewAmsterdam Pharma Company Transcript: Investor Day 2026

Aug 5, 2026, 9:00 AM EDT - 14 days ago

NewAmsterdam Pharma Company Slides: FY 2026

Aug 5, 2026, 7:00 AM EDT - 14 days ago

NewAmsterdam Pharma Provides Corporate Update and Reports Second Quarter Financial Results

Aug 5, 2026, 7:00 AM EDT - 14 days ago

NewAmsterdam Pharma Company Quarterly report: Q2 2026

Aug 5, 2026, 7:00 AM EDT - 14 days ago

NewAmsterdam Pharma Company Earnings release: Q2 2026

Jul 29, 2026, 8:00 AM EDT - 21 days ago

NewAmsterdam Pharma to Host Investor Day on August 5, 2026

2026-07-24T14:20:12.000Z - 26 days ago

NewAmsterdam announces positive CHMP opinion for Ubeslo and Evlarco

Jul 24, 2026, 8:00 AM EDT - 26 days ago

NewAmsterdam Pharma and Menarini Group Receive Positive CHMP Opinion Recommending Marketing Authorization for Ubeslo® (Obicetrapib Monotherapy) and Evlarco® (Obicetrapib Plus Ezetimibe Fixed-Dose Combination)

2026-07-20T20:50:23.000Z - 4 weeks ago

NewAmsterdam Pharma initiated with an Outperform at BMO Capital

Jul 2, 2026, 4:01 PM EDT - 6 weeks ago

NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jul 1, 2026, 8:00 AM EDT - 7 weeks ago

NewAmsterdam Pharma Announces Upcoming Presentations at the Alzheimer's Association International Conference (AAIC) 2026

2026-06-30T11:05:14.000Z - 7 weeks ago

NewAmsterdam Pharma price target raised to $51 from $47 at RBC Capital

Jun 9, 2026, 2:40 PM EDT - 2 months ago

NewAmsterdam Pharma Company Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026

Jun 3, 2026, 10:30 AM EDT - 2 months ago

NewAmsterdam Pharma Company Transcript: Jefferies Global Healthcare Conference 2026

Jun 3, 2026, 8:00 AM EDT - 2 months ago

NewAmsterdam Pharma Announces Upcoming Presentations at the National Lipid Association (NLA) 2026 Scientific Sessions

May 28, 2026, 8:00 AM EDT - 2 months ago

NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in June

May 20, 2026, 2:05 PM EDT - 3 months ago

NewAmsterdam Pharma Company Transcript: RBC Capital Markets Global Healthcare Conference 2026

May 12, 2026, 8:15 PM EDT - 3 months ago

NewAmsterdam Pharma Company Transcript: Bank of America Global Healthcare Conference 2026

May 11, 2026, 8:41 AM EDT - 3 months ago

NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in May

May 7, 2026, 8:00 AM EDT - 3 months ago

NewAmsterdam Pharma Company Transcript: Investor update

May 7, 2026, 8:00 AM EDT - 3 months ago

NewAmsterdam Pharma Company Slides: Investor update

May 7, 2026, 7:00 AM EDT - 3 months ago

NewAmsterdam Pharma Provides Corporate Update and Reports First Quarter Financial Results

May 7, 2026, 7:00 AM EDT - 3 months ago

NewAmsterdam Pharma Company Quarterly report: Q1 2026

May 7, 2026, 7:00 AM EDT - 3 months ago

NewAmsterdam Pharma Company Earnings release: Q1 2026

May 6, 2026, 8:00 AM EDT - 3 months ago

NewAmsterdam Pharma Company Proxy statement: Proxy filing

Apr 20, 2026, 8:00 AM EDT - 4 months ago

NewAmsterdam Pharma Company Proxy statement: Proxy filing

Apr 13, 2026, 11:45 AM EDT - 4 months ago

NewAmsterdam Pharma Company Transcript: 25th Annual Needham Virtual Healthcare Conference

Apr 8, 2026, 8:00 AM EDT - 4 months ago

NewAmsterdam Pharma to Present at the 25th Annual Needham Virtual Healthcare Conference

Mar 23, 2026, 8:00 AM EDT - 5 months ago

NewAmsterdam Pharma Announces Three Presentations at the 2026 American College of Cardiology Annual Scientific Session

2026-03-18T19:50:17.000Z - 5 months ago

NewAmsterdam Pharma initiated with a Buy at Truist

Mar 9, 2026, 8:40 AM EDT - 5 months ago

NewAmsterdam Pharma Company Transcript: Leerink Global Healthcare Conference 2026

Mar 3, 2026, 10:30 AM EST - 6 months ago

NewAmsterdam Pharma Company Transcript: TD Cowen 46th Annual Health Care Conference

Mar 2, 2026, 6:00 AM EST - 6 months ago

NewAmsterdam Pharma Company Slides: Corporate presentation

Feb 25, 2026, 8:00 AM EST - 6 months ago

NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in March

2026-02-19T12:25:00.000Z - 6 months ago

NewAmsterdam Pharma price target raised to $45 from $41 at Guggenheim

Feb 18, 2026, 7:00 AM EST - 6 months ago

NewAmsterdam Pharma Reports Full Year 2025 Financial Results and Provides Corporate Update

Feb 18, 2026, 7:00 AM EST - 6 months ago

NewAmsterdam Pharma Company Earnings release: Q4 2025

Feb 18, 2026, 7:00 AM EST - 6 months ago

NewAmsterdam Pharma Company Annual report: Q4 2025

Feb 11, 2026, 8:30 AM EST - 6 months ago

NewAmsterdam Pharma Company Transcript: Guggenheim Securities Emerging Outlook: Biotech Summit 2026

Feb 4, 2026, 8:00 AM EST - 7 months ago

NewAmsterdam Pharma to Present at the Guggenheim Emerging Outlook: Biotech Summit

2026-01-21T11:41:16.000Z - 7 months ago

NewAmsterdam Pharma price target raised to $47 from $44 at RBC Capital

2026-01-09T13:10:50.000Z - 7 months ago

NewAmsterdam Pharma highlights 2025 achievements, 2026 priorities

Jan 9, 2026, 8:00 AM EST - 7 months ago

NewAmsterdam Pharma Highlights 2025 Achievements and Outlines 2026 Strategic Priorities

Dec 4, 2025, 8:00 AM EST - 9 months ago

NewAmsterdam Pharma Company Transcript: Piper Sandler 37th Annual Healthcare Conference

Dec 3, 2025, 3:15 PM EST - 9 months ago

NewAmsterdam Pharma Company Transcript: Citi Annual Global Healthcare Conference 2025

Dec 2, 2025, 3:50 PM EST - 9 months ago

NewAmsterdam Pharma Company Transcript: Evercore ISI 8th Annual HealthCONx Conference

2025-12-02T11:41:05.000Z - 9 months ago

NewAmsterdam Pharma price target raised to $37 from $30 at Goldman Sachs

Nov 25, 2025, 8:00 AM EST - 9 months ago

NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in December

Nov 19, 2025, 7:00 AM EST - 9 months ago

NewAmsterdam Pharma Company Transcript: Jefferies London Healthcare Conference 2025

Nov 12, 2025, 8:00 AM EST - 10 months ago

NewAmsterdam Pharma Company Transcript: Stifel 2025 Healthcare Conference

Nov 11, 2025, 10:30 AM EST - 10 months ago

NewAmsterdam Pharma Company Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference

Nov 5, 2025, 8:00 AM EST - 10 months ago

NewAmsterdam Pharma Provides Corporate Update and Reports Third Quarter Financial Results

Nov 5, 2025, 7:00 AM EST - 10 months ago

NewAmsterdam Pharma Company Earnings release: Q3 2025

Nov 5, 2025, 7:00 AM EST - 10 months ago

NewAmsterdam Pharma Company Quarterly report: Q3 2025

Oct 30, 2025, 8:00 AM EDT - 10 months ago

NewAmsterdam Pharma to Participate in Upcoming Medical Meeting and Investor Conferences in November

2025-10-20T10:20:42.000Z - 10 months ago

NewAmsterdam Pharma assumed with a Buy at H.C. Wainwright

2025-10-17T10:20:31.000Z - 10 months ago

NewAmsterdam Pharma price target raised to $50 from $42 at Citi

Sep 30, 2025, 11:00 AM EDT - 11 months ago

NewAmsterdam Pharma Company Transcript: Stifel Virtual Cardiometabolic Forum

Sep 24, 2025, 8:00 AM EDT - 11 months ago

NewAmsterdam Pharma to Present at the Stifel 2025 Virtual Cardiometabolic Forum

Sep 5, 2025, 10:15 AM EDT - 1 year ago

NewAmsterdam Pharma Company Transcript: Wells Fargo 20th Annual Healthcare Conference 2025

Sep 4, 2025, 2:45 PM EDT - 1 year ago

NewAmsterdam Pharma Company Transcript: Cantor Global Healthcare Conference 2025

Sep 3, 2025, 2:30 PM EDT - 1 year ago

NewAmsterdam Pharma Company Transcript: Citi's Biopharma Back to School Conference

Aug 25, 2025, 8:00 AM EDT - 1 year ago

NewAmsterdam Pharma to Participate in Upcoming Medical Meeting and Investor Conferences in September

2025-08-25T09:55:09.000Z - 1 year ago

NewAmsterdam Pharma initiated with an Overweight at Wells Fargo

Aug 21, 2025, 2:41 AM EDT - 1 year ago

Piramal Pharma Solutions and NewAmsterdam Pharma Invest in Dedicated Suite to Enhance Oral Solid Dosage Production Capabilities at Piramal's Sellersville, Pennsylvania Site

Aug 18, 2025, 8:00 AM EDT - 1 year ago

NewAmsterdam Announces Acceptance of Marketing Authorization Applications for Review by European Medicine Agency for Obicetrapib

Aug 6, 2025, 7:00 AM EDT - 1 year ago

NewAmsterdam Pharma Company Earnings release: Q2 2025

Aug 6, 2025, 7:00 AM EDT - 1 year ago

NewAmsterdam Pharma Company Quarterly report: Q2 2025

Jul 30, 2025, 10:00 AM EDT - 1 year ago

NewAmsterdam Pharma Company Transcript: Status Update

Jul 30, 2025, 10:00 AM EDT - 1 year ago

NewAmsterdam Pharma Company Press release: Status Update

Jul 30, 2025, 10:00 AM EDT - 1 year ago

NewAmsterdam Pharma Company Slides: Status Update

Jul 30, 2025, 8:25 AM EDT - 1 year ago

NewAmsterdam Pharma Presents Positive Data from BROADWAY Trial Demonstrating Statistically Significant Reductions in Key Alzheimer's Disease Biomarkers at AAIC 2025

Jul 22, 2025, 8:00 AM EDT - 1 year ago

NewAmsterdam Pharma to Present Alzheimer's Biomarker Data from BROADWAY Trial at AAIC 2025

Jun 11, 2025, 9:00 AM EDT - 1 year ago

NewAmsterdam Pharma Company Transcript: R&D Day 2025

Jun 11, 2025, 9:00 AM EDT - 1 year ago

NewAmsterdam Pharma Company Slides: FY 2025

Jun 9, 2025, 2:40 PM EDT - 1 year ago

NewAmsterdam Pharma Company Transcript: Goldman Sachs 46th Annual Global Healthcare Conference

Jun 9, 2025, 7:00 AM EDT - 1 year ago

NewAmsterdam Pharma Announces Positive Topline Alzheimer's Disease Data from BROADWAY Clinical Trial

Jun 5, 2025, 8:00 AM EDT - 1 year ago

NewAmsterdam Pharma to Host R&D Day on June 11, 2025

Jun 4, 2025, 10:30 AM EDT - 1 year ago

NewAmsterdam Pharma Company Transcript: Jefferies Global Healthcare Conference 2025

Jun 3, 2025, 4:20 PM EDT - 1 year ago

NewAmsterdam Pharma Company Transcript: 45th Annual William Blair Growth Stock Conference

May 14, 2025, 8:00 AM EDT - 1 year ago

NewAmsterdam Pharma to Present at the 2025 RBCCM Global Healthcare Conference

May 8, 2025, 8:00 AM EDT - 1 year ago

NewAmsterdam Pharma Company Earnings release: Q1 2025

May 8, 2025, 8:00 AM EDT - 1 year ago

NewAmsterdam Pharma Company Quarterly report: Q1 2025

May 8, 2025, 8:00 AM EDT - 1 year ago

NewAmsterdam Pharma Company Proxy statement: Proxy Filing

May 7, 2025, 7:15 AM EDT - 1 year ago

NewAmsterdam Pharma Announces Late-Breaking Data from BROADWAY and TANDEM Pivotal Studies Published in Leading Medical Journals and Presented at the European Atherosclerosis Society (EAS) Congress 2025

Apr 30, 2025, 8:00 AM EDT - 1 year ago

NewAmsterdam Pharma to Present New Clinical and Preclinical Data at 93rd EAS Congress

Apr 28, 2025, 8:00 AM EDT - 1 year ago

NewAmsterdam Pharma Company Proxy statement: Proxy Filing

Apr 7, 2025, 12:45 PM EDT - 1 year ago

NewAmsterdam Pharma Company Transcript: 24th Annual Needham Virtual Healthcare Conference

Mar 31, 2025, 8:00 AM EDT - 1 year ago

NewAmsterdam Pharma to Present at the 24th Annual Needham Virtual Healthcare Conference

Mar 10, 2025, 8:00 AM EDT - 1 year ago

NewAmsterdam Pharma Company Transcript: Leerink Global Healthcare Conference 2025

Mar 4, 2025, 1:50 PM EST - 1 year ago

NewAmsterdam Pharma Company Transcript: TD Cowen 45th Annual Healthcare Conference

Feb 28, 2025, 7:00 AM EST - 1 year ago

NewAmsterdam Pharma Company Registration statement: Registration Filing

Feb 26, 2025, 8:00 AM EST - 1 year ago

NewAmsterdam Pharma Reports Full Year 2024 Financial Results and Provides Corporate Update

Feb 26, 2025, 8:00 AM EST - 1 year ago

NewAmsterdam Pharma Company Earnings release: Q4 2024

Feb 26, 2025, 8:00 AM EST - 1 year ago

NewAmsterdam Pharma Company Annual report: Q4 2024

Feb 5, 2025, 10:00 AM EST - 1 year ago

NewAmsterdam Pharma Company Transcript: Guggenheim SMID Cap Biotech Conference

Jan 10, 2025, 12:00 AM EST - 1 year ago

NewAmsterdam Pharma Company Slides: Corporate Presentation

Dec 13, 2024, 5:16 PM EST - 1 year ago

NewAmsterdam Pharma Announces Closing of Upsized $479.0 Million Public Offering of Ordinary Shares and Pre-Funded Warrants, Including Full Exercise of the Underwriters' Option to Purchase Additional Shares

Dec 11, 2024, 9:37 PM EST - 1 year ago

NewAmsterdam Pharma Announces Pricing of Upsized $416.5 Million Public Offering of Ordinary Shares and Pre-Funded Warrants

Dec 10, 2024, 4:34 PM EST - 1 year ago

NewAmsterdam Pharma Announces Commencement of $300 Million Public Offering of Ordinary Shares and Pre-Funded Warrants

Dec 10, 2024, 8:00 AM EST - 1 year ago

NewAmsterdam Pharma Company Transcript: Status Update

Dec 10, 2024, 8:00 AM EST - 1 year ago

NewAmsterdam Pharma Company Press release: Status Update

Dec 10, 2024, 8:00 AM EST - 1 year ago

NewAmsterdam Pharma Company Slides: Status Update

Dec 10, 2024, 7:00 AM EST - 1 year ago

NewAmsterdam Pharma Announces Positive Topline Data from Pivotal Phase 3 BROADWAY Clinical Trial Evaluating Obicetrapib in Patients with Atherosclerotic Cardiovascular Disease and/or Heterozygous Familial Hypercholesterolemia

Nov 21, 2024, 8:00 AM EST - 1 year ago

NewAmsterdam Pharma Company Transcript: Jefferies London Healthcare Conference 2024

Nov 20, 2024, 8:10 AM EST - 1 year ago

NewAmsterdam Pharma Company Transcript: Study Update

Nov 20, 2024, 8:10 AM EST - 1 year ago

NewAmsterdam Pharma Company Press release: Study Update

Nov 20, 2024, 8:10 AM EST - 1 year ago

NewAmsterdam Pharma Company Slides: Study Update

Nov 18, 2024, 3:20 PM EST - 1 year ago

NewAmsterdam Pharma Presents Additional Data from Pivotal Phase 3 BROOKLYN Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia at AHA Scientific Sessions 2024

Nov 18, 2024, 3:15 PM EST - 1 year ago

NewAmsterdam Pharma Company Slides: Investor Presentation

Nov 6, 2024, 8:00 AM EST - 1 year ago

NewAmsterdam Pharma Company Quarterly report: Q3 2024

Nov 6, 2024, 8:00 AM EST - 1 year ago

NewAmsterdam Pharma Company Earnings release: Q3 2024

Oct 28, 2024, 4:30 PM EDT - 1 year ago

NewAmsterdam Pharma to Participate in Upcoming Medical and Investor Conferences in November

Sep 17, 2024, 3:40 PM EDT - 2 years ago

NewAmsterdam Pharma Company Transcript: 2024 Cantor Fitzgerald Global Healthcare Conference

Aug 30, 2024, 8:00 AM EDT - 2 years ago

NewAmsterdam Pharma to Participate in Upcoming Investor Conferences in September

Aug 7, 2024, 7:00 AM EDT - 2 years ago

NewAmsterdam Pharma Company Quarterly report: Q2 2024

Aug 7, 2024, 7:00 AM EDT - 2 years ago

NewAmsterdam Pharma Company Earnings release: Q2 2024

Jul 29, 2024, 8:30 AM EDT - 2 years ago

NewAmsterdam Pharma Company Transcript: Study Update

Jul 29, 2024, 8:30 AM EDT - 2 years ago

NewAmsterdam Pharma Company Press release: Study Update

Jul 29, 2024, 8:30 AM EDT - 2 years ago

NewAmsterdam Pharma Company Slides: Study Update

Jul 26, 2024, 4:01 PM EDT - 2 years ago

NewAmsterdam Pharma to Announce Topline Data from Pivotal Phase 3 BROOKLYN Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia on Monday, July 29, 2024

Jul 8, 2024, 8:00 AM EDT - 2 years ago

NewAmsterdam Pharma Completes Enrollment in Pivotal Phase 3 TANDEM Clinical Trial Evaluating Fixed-Dose Combination of Obicetrapib plus Ezetimibe in Patients with HeFH and/or ASCVD or ASCVD Risk Factors

Jul 3, 2024, 8:00 AM EDT - 2 years ago

NewAmsterdam Pharma Company Registration statement: Registration Filing

Jun 10, 2024, 10:40 AM EDT - 2 years ago

NewAmsterdam Pharma Company Transcript: Goldman Sachs 45th Annual Global Healthcare Conference

Jun 10, 2024, 10:40 AM EDT - 2 years ago

NewAmsterdam Pharma Company Slides: Goldman Sachs 45th Annual Global Healthcare Conference

Jun 5, 2024, 3:00 PM EDT - 2 years ago

NewAmsterdam Pharma Company Transcript: Jefferies 2024 Global Healthcare Conference

May 16, 2024, 9:00 AM EDT - 2 years ago

NewAmsterdam Pharma Company Transcript: R&D Day

May 16, 2024, 9:00 AM EDT - 2 years ago

NewAmsterdam Pharma Company Slides: R&D Day

May 14, 2024, 4:35 PM EDT - 2 years ago

NewAmsterdam Pharma Company Transcript: 2024 RBC Capital Markets Global Healthcare Conference

May 9, 2024, 8:00 AM EDT - 2 years ago

NewAmsterdam Pharma Company Proxy statement: Proxy Filing

May 9, 2024, 7:00 AM EDT - 2 years ago

NewAmsterdam Pharma Company Quarterly report: Q1 2024

May 9, 2024, 7:00 AM EDT - 2 years ago

NewAmsterdam Pharma Company Earnings release: Q1 2024

Apr 29, 2024, 8:00 AM EDT - 2 years ago

NewAmsterdam Pharma Company Proxy statement: Proxy Filing

Apr 9, 2024, 8:00 AM EDT - 2 years ago

NewAmsterdam Pharma Enrolls Over 9,000 Patients in Pivotal Phase 3 PREVAIL Global Cardiovascular Outcome Trial Evaluating the Effect of Obicetrapib in Patients with Established Atherosclerotic Cardiovascular Disease

Apr 9, 2024, 8:00 AM EDT - 2 years ago

BioAge Appoints Renowned Cardiologist and Biopharma Entrepreneur Michael H. Davidson, MD, to its Board of Directors

Apr 1, 2024, 8:00 AM EDT - 2 years ago

NewAmsterdam Pharma Announces the Appointment of Juliette Audet as Chief Business Officer

Mar 25, 2024, 8:00 AM EDT - 2 years ago

NewAmsterdam Pharma to Present New Analysis from the Phase 2 ROSE2 Trial Evaluating Obicetrapib in Combination with Ezetimibe at 2024 American College of Cardiology Congress

Mar 12, 2024, 8:00 AM EDT - 2 years ago

NewAmsterdam Pharma Doses First Patient in Phase 3 TANDEM Clinical Trial Evaluating Fixed-Dose Combination of Obicetrapib and Ezetimibe in Patients with HeFH and/or ASCVD

Mar 11, 2024, 4:00 PM EDT - 2 years ago

NewAmsterdam Pharma Company Transcript: Leerink Partners Global Biopharma Conference 2024

Mar 4, 2024, 2:10 PM EST - 2 years ago

NewAmsterdam Pharma Company Transcript: TD Cowen 44th Annual Health Care Conference 2024

Feb 28, 2024, 8:00 AM EST - 2 years ago

NewAmsterdam Pharma Reports Full Year 2023 Financial Results and Provides Corporate Update

Feb 28, 2024, 7:00 AM EST - 2 years ago

NewAmsterdam Pharma Company Earnings release: Q4 2023

Feb 28, 2024, 7:00 AM EST - 2 years ago

NewAmsterdam Pharma Company Annual report: Q4 2023

Feb 13, 2024, 10:40 PM EST - 2 years ago

NewAmsterdam Pharma Announces Pricing of $175.3 Million Public Offering of Ordinary Shares and Pre-Funded Warrants

Feb 13, 2024, 4:01 PM EST - 2 years ago

NewAmsterdam Pharma Announces Commencement of Public Offering of Ordinary Shares and Pre-Funded Warrants

Feb 7, 2024, 1:00 PM EST - 2 years ago

NewAmsterdam Pharma Company Transcript: Guggenheim Healthcare Talks | 6th Annual Biotechnology Conference

Feb 1, 2024, 4:01 PM EST - 2 years ago

NewAmsterdam Pharma to Present at Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

Jan 4, 2024, 8:00 AM EST - 2 years ago

NewAmsterdam Pharma Announces 2024 Strategic Priorities

JFDI Aug. 19 at 7:48 PM

$NAMS base on base

0 · Reply

Good2go Aug. 18 at 3:43 PM

$EIX $EBAY $ENB even $NAMS All in the green today oddly enough.

0 · Reply

profitsforall Aug. 17 at 8:45 PM

$NAMS NOW now..below $32.X

0 · Reply

profitsforall Aug. 17 at 8:44 PM

$NAMS

0 · Reply

appayip Aug. 17 at 9:45 AM

$NAMS what is the price you would add or open position?

1 · Reply

CH_Expat Aug. 17 at 8:49 AM

$NAMS @masonat Thoughts about the 500k put position from Perceptive Advisors?

2 · Reply

Finlay2 Aug. 14 at 5:03 PM

$NAMS hey guys - anyone worried about the decrease in small hdl particles with obi?

1 · Reply

cubie Aug. 13 at 4:41 PM

1 · Reply

newfguy Aug. 7 at 12:25 AM

$NAMS watched all 3 hours of investor day presentation. EU launch end of 26/early 27. US NDA w FDA first half 27. patience will be rewarded

0 · Reply

newfguy Aug. 6 at 9:24 PM

$NAMS 1.65M shares traded today

0 · Reply

masonat Aug. 5 at 6:33 PM

$NAMS Investor day disappointing for me. Didn't really provide me with any new information. Was hoping to be more confident in interim after today but they didn't provide any additional data to help there. Certainly worth a listen for those newer to the company though.

1 · Reply

d_risk Aug. 5 at 2:42 PM

$NAMS - NewAmsterdam Pharma Company N.V - 10Q - Updated Risk Factors NAMS now flags added risks from Medicaid cuts and work requirements under OBBBA that could hurt future product sales, potential MFN-style pricing pressure from earlier launches in low-price markets, and possible new U.S. tariffs on foreign-made drug ingredients after a national security review. #PharmaceuticalIndustry #MedicaidRisks #PricingPressure #U.S.Tariffs #RegulatoryCompliance 🟢 Added 🟠 Removed https://d-risk.ai/NAMS/10-Q/2026-08-05

0 · Reply

Finlay2 Aug. 5 at 1:40 PM

$NAMS Woah. Investor day must not be going to hot

2 · Reply

Finlay2 Aug. 3 at 1:37 PM

$NAMS continues to tank on no news. Puzzling

3 · Reply

profitsforall Jul. 31 at 12:39 PM

$NAMS Is there a more active NAMS discussion group

3 · Reply

newfguy Jul. 30 at 2:14 PM

$NAMS sell me your shares

1 · Reply

newfguy Jul. 29 at 10:34 PM

$NAMS Merck oral PCSK9 drug: $315/month, $10.50 a tablet, needs 6-8 hours fasting and no food for 30 mins after dose. Has different mechanism of action than injectable PCSK9 so can't assume same CV outcomes as injectable. CV outcome trial doesn't report till 2029. Obicetrapib better on so many counts and has real potential for Alzheimer's indication in future. Adding to position

1 · Reply

Eddyg987 Jul. 29 at 3:35 PM

$NAMS what price will this drug sell at? such a niche when it comes to cholesterol, but I want this drug ASAP as I believe it's a longevity drug and great for apoe4 Alzheimer's prevention.

0 · Reply

newfguy Jul. 28 at 3:12 PM

$NAMS weakness on low volume. another good entry point. EU approval near term catalyst. Merck drug approval may have contributed to recent price decline

0 · Reply

CH_Expat Jul. 28 at 2:00 PM

Okay guys, new prime candidates for starters (at lower valuations of course) are $NAMS -$NRIX - $IMTX - $CLDX and CELC. Than we have some others, but far away from my entry points. IDYA and MLYS unchanged.

4 · Reply

8869scy Jul. 25 at 10:35 PM

$NAMS heavy mid 20s puts for August, not one but now two top executives leaving in August, and heavy continuous insider selling with zero buying has kept me from adding more. I am bullish but can't ignore the above.

1 · Reply

CH_Expat Jul. 25 at 5:40 PM

$NAMS Probs to @masonat. Legend. Helped me big time on my DD.

1 · Reply

1.0.0